Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marshal Irby

Pulmonary Disease Monroe, LA Medical Doctor

NPI 1679560411 CMS profile 257631

2810 Armand, Monroe, LA 71201

Open in the dashboard

General payments

$5,010

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marshal Irby of Monroe, LA is reported in the CMS Open Payments database as having received $5,010 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $607 29
2024 General $576 26
2023 General $513 27
2022 General $877 41
2021 General $523 32
2020 General $659 37
2019 General $1,255 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marshal Irby
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Marshal Irby were reported at $607. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Marshal Irby Pulmonary Disease median Middle half National median
2019 $1,255 $377 $109–$1,340 $163
2020 $659 $230 $56–$907 $114
2021 $523 $269 $68–$1,072 $132
2022 $877 $390 $100–$1,457 $149
2023 $513 $419 $114–$1,659 $160
2024 $576 $476 $123–$1,818 $164
2025 $607 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,357 79 payments
  2. AstraZeneca Pharmaceuticals LP $1,268 50 payments
  3. Mylan Specialty L.P. $800 40 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $422 25 payments
  5. Grifols USA, LLC $298 15 payments
  6. Insmed, Inc. $180 10 payments
  7. Verona Pharma, Inc. $115 5 payments
  8. Inogen, Inc. $97 6 payments
  9. Mallinckrodt Enterprises LLC $90 4 payments
  10. Advanced Respiratory, Inc $89 4 payments
  11. Other $293 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,889 244 payments
  2. Education $121 8 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,053 64 payments
  2. YUPELRI Anticholinergics, Inhaled $575 28 payments
  3. SPIRIVA RESPIMAT $366 22 payments
  4. FASENRA Respiratory $341 14 payments
  5. Prolastin-C Liquid $298 15 payments
  6. Yupelri Respiratory and Allergy $284 15 payments
  7. TEZSPIRE $274 4 payments
  8. FASENRA Respiratory $259 13 payments
  9. BREZTRI $255 11 payments
  10. Perforomist $245 13 payments
  11. Other $1,849 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,666

Median for Internal Medicine: 777

Drug cost

$975,601

Median for Internal Medicine: $73,373

Branded share of claims

71.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prolastin C Alpha-1-Proteinase Inhibitor Brand 29 $371,319
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 225 $203,785
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 202 $112,036
Spiriva Respimat Tiotropium Bromide Brand 117 $78,162
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 112 $59,528
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 57 $49,207
Incruse Ellipta Umeclidinium Bromide Brand 93 $42,341
Breo Ellipta Fluticasone/Vilanterol Brand 76 $36,832
Symbicort Budesonide/Formoterol Fumarate Brand 20 $6,925
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 28 $4,621

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$82,775

Medicare's payments for the services billed

Medicare patients

426

Average age 75

Services billed

1,260

194 women, 232 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 52%
COPD 48%
Diabetes 41%
Atrial fibrillation 32%
Chronic kidney disease 28%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YUPELRI
  • Mylan Specialty L.P. $143
$143 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $97
$97 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $76
$76 — —
AREXVY
  • GlaxoSmithKline, LLC. $63
$63 — —
Arikayce
  • Insmed, Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record